| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Naloxone-d5 targets opioid receptors as a potent antagonist. As a deuterated form of naloxone, it retains the same pharmacological activity as the parent compound, which is a competitive antagonist at mu, kappa, and delta opioid receptors. Naloxone reverses the effects of opioid agonists by displacing them from opioid receptors. The deuterium labeling does not significantly alter the binding affinity or pharmacological profile of the compound, making it suitable as an internal standard for analytical applications.
|
|---|---|
| ln Vitro |
In vitro studies of Naloxone-d5 are primarily focused on its use as an analytical standard rather than its pharmacological activity. As a deuterated analog of naloxone, it retains the same receptor binding properties as the parent compound. Naloxone is a potent opioid receptor antagonist that competitively binds to mu, kappa, and delta opioid receptors. In vitro characterization includes receptor binding assays to confirm its affinity and selectivity for opioid receptors. The compound is used in analytical method development and validation for the quantification of naloxone in biological samples.
|
| ln Vivo |
In vivo studies of Naloxone-d5 are limited, as the compound is primarily used as an analytical internal standard rather than for pharmacological studies. As a deuterated form of naloxone, it would be expected to exhibit the same in vivo activity as the parent compound, which is a potent opioid receptor antagonist used to reverse opioid overdose. Naloxone is administered intravenously, intramuscularly, or intranasally and has a rapid onset of action. However, Naloxone-d5 itself is not typically used for in vivo pharmacological studies due to its role as an analytical standard.
|
| Enzyme Assay |
For analytical method development, Naloxone-d5 is used as an internal standard for the quantification of naloxone by GC-MS or LC-MS. The compound is dissolved in appropriate solvents and spiked into biological samples (e.g., plasma, urine) at known concentrations. Samples are processed using standard extraction procedures (e.g., solid-phase extraction or liquid-liquid extraction). The extracted samples are analyzed by GC-MS or LC-MS with selected ion monitoring (SIM) or multiple reaction monitoring (MRM) for the deuterated and non-deuterated compounds. Calibration curves are generated by plotting the peak area ratio of naloxone to Naloxone-d5 against the concentration of naloxone.
|
| Cell Assay |
For in vitro cellular assays, Naloxone-d5 is not typically used due to its role as an analytical standard. However, for receptor binding studies, cell lines expressing opioid receptors (e.g., CHO or HEK293 cells) can be cultured in appropriate media under standard conditions (37°C, 5% CO2). Naloxone-d5 is dissolved in DMSO and diluted in assay buffer to desired concentrations. Receptor binding is assessed using radiolabeled ligands and competition binding assays. Each concentration is tested in replicate wells with vehicle controls and positive controls (e.g., naloxone).
|
| Animal Protocol |
For in vivo animal studies of Naloxone-d5, no specific protocols are available as the compound is primarily used as an analytical internal standard. For general in vivo administration of naloxone, the compound is formulated in suitable vehicles and administered via intravenous (i.v.), intramuscular (i.m.), or intranasal routes. Dosing regimens vary by study objective. For opioid reversal studies, animals are treated with opioid agonists followed by naloxone administration, and physiological responses are monitored. All procedures must follow institutional animal care and use committee guidelines.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Naloxone-d5 are similar to those of naloxone. The compound has a molecular weight of 332.41 and formula C19H16D5NO4. CAS number: 1261079-38-2. Purity: ≥96%. Isotopic enrichment: >98%. Appearance: typically exists as solid at room temperature. Melting point: >155°C (decomposes). LogP: 1.239. Storage: powder at -20°C for 3 years or 4°C for 2 years; in solvent at -80°C for 6 months or -20°C for 1 month. Solubility: may dissolve in DMSO.
|
| Toxicity/Toxicokinetics |
According to available safety information, Naloxone-d5 is intended for research purposes only and is not for human use. Standard laboratory safety precautions should be followed when handling this compound, including the use of appropriate personal protective equipment (gloves, lab coat, safety goggles). The compound should be handled in a well-ventilated area. Avoid dust formation and inhalation. In case of skin contact, wash with plenty of soap and water. In case of eye contact, rinse cautiously with water for several minutes. No clinical toxicity data are available.
|
| Additional Infomation |
Naloxone-d5 is a deuterated compound standard of naloxone, a potent opioid receptor antagonist. It is intended for use as an internal standard for the quantification of naloxone by GC- or LC-MS. Naloxone is used clinically to reverse opioid overdose. Naloxone-d5 has a molecular weight of 332.41 and formula C19H16D5NO4. It is for research use only with no clinical development or regulatory approvals reported as a therapeutic agent.
|
| Molecular Formula |
C19H16D5NO4
|
|---|---|
| Molecular Weight |
332.41
|
| Exact Mass |
332.178
|
| CAS # |
1261079-38-2
|
| Related CAS # |
Naloxone hydrochloride;357-08-4;Naloxone;465-65-6
|
| PubChem CID |
71750914
|
| Appearance |
Typically exists as solid at room temperature
|
| Melting Point |
>155°C (分解)
|
| LogP |
1.239
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
24
|
| Complexity |
594
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
C([2H])([2H])=C([2H])C([2H])([2H])N1CC[C@@]23C4=C5C=CC(=C4O[C@H]3C(=O)CC[C@]2([C@H]1C5)O)O
|
| InChi Key |
UZHSEJADLWPNLE-HEEDNVRVSA-N
|
| InChi Code |
InChI=1S/C19H21NO4/c1-2-8-20-9-7-18-15-11-3-4-12(21)16(15)24-17(18)13(22)5-6-19(18,23)14(20)10-11/h2-4,14,17,21,23H,1,5-10H2/t14-,17+,18+,19-/m1/s1/i1D2,2D,8D2
|
| Chemical Name |
(4R,4aS,7aR,12bS)-4a,9-dihydroxy-3-(1,1,2,3,3-pentadeuterioprop-2-enyl)-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0083 mL | 15.0417 mL | 30.0833 mL | |
| 5 mM | 0.6017 mL | 3.0083 mL | 6.0167 mL | |
| 10 mM | 0.3008 mL | 1.5042 mL | 3.0083 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
